PMID- 25200044 OWN - NLM STAT- MEDLINE DCOM- 20150330 LR - 20140909 IS - 1001-0939 (Print) IS - 1001-0939 (Linking) VI - 37 IP - 6 DP - 2014 Jun TI - [The effect of low molecular heparin and urokinase on MCP-1 of acute experimental pulmonary embolism in rabbits]. PG - 437-41 AB - OBJECTIVE: To evaluate effect the of thrombolytic (urokinase, UK) and anticoagulant agent (low-molecular-weight heparin, LMWH) on the pulmonary injury of rabbits with acute pulmonary embolism (PE) by assaying monocyte chemoattractant protein-1 (MCP-1). METHODS: Rabbit models with PE were established by transfusing autologous blood clots on 60 healthy male Japanese white rabbits. Experimental PE rabbits were randomly divided into 3 groups:normal saline (NS) group (n = 18) , LMWH group (n = 18) and UK group (n = 18), and other 18 rabbits underwent sham operations as SHAM group (n = 18). Each group was divided into 3 subgroups based on 2 days (day 2), 4 days (day 4), and 14 days (day 14) after therapies. Arterial blood gas analysis was measured. MCP-1 levels in lung tissue and blood were assayed with ELISA at various times (day 2, day 4 and day 14 ). Fixed sections were stained with trichrome for intimal hyperplasia determination. RESULTS: The overall rate of success for making PE rabbit models was 90% (54/60), which was not affected by treatment. Compared with NS group, P(A-a)O2 significantly decreased in UK group. Compared with NS group, MCP-1 levels in lung tissue significantly decreased in LMWH group on day 4 [(33 +/- 9) ng/L vs (48 +/- 5) ng/L, P < 0.05] and day 14 [(30 +/- 11) ng/L vs (41 +/- 4) ng/L, P < 0.05]; MCP-1 levels in serum on day 14 also significantly decreased in LMWH group [(36 +/- 10) ng/L vs (51 +/- 5) ng/L, P < 0.05]. Compared with NS group, MCP-1 levels in lung tissue significantly decreased in UK group on day 2 and 4 [Day 2: (34 +/- 8) ng/L vs (50 +/- 4) ng/L, P < 0.05; Day 4: (29 +/- 7) ng/L vs (48 +/- 5) ng/L, P < 0.05]; MCP-1 levels in serum on day 2 and day 4 also significantly decreased in UK group [Day 2: (44 +/- 3) ng/L vs (48 +/- 3) ng/L, P < 0.05; Day 4: (44 +/- 4) ng/L vs (53 +/- 1)ng/L, P < 0.05]. CONCLUSIONS: UK treatment may rapidly improve V/Q ratio and decrease MCP-1 levels in lung tissue or serum, but it can not inhibit persistent inflammation. LMWH can decrease MCP-1 levels in lung tissue or serum, and inhibit persistent inflammation and late intimal hyperplasia. FAU - Yu, Hongzhi AU - Yu H AD - Department of Respiratory Medicine, Tianjin Haihe Hospital, Tianjin 300350, China. FAU - Wu, Qi AU - Wu Q AD - Department of Respiratory Medicine, General Hospital of Tianjin Medical University, Tianjin 300052, China. Email: wq572004@163.com. FAU - Wu, Junping AU - Wu J FAU - Sun, Xin AU - Sun X FAU - Du, Zhongzhen AU - Du Z FAU - Li, Li AU - Li L FAU - Wu, Qian AU - Wu Q LA - chi PT - English Abstract PT - Journal Article PL - China TA - Zhonghua Jie He He Hu Xi Za Zhi JT - Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases JID - 8712226 RN - 0 (Chemokine CCL2) RN - 0 (Fibrinolytic Agents) RN - 0 (Heparin, Low-Molecular-Weight) RN - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator) SB - IM MH - Acute Disease MH - Animals MH - Chemokine CCL2/blood/*metabolism MH - Disease Models, Animal MH - Endothelium, Vascular/drug effects/pathology MH - Enzyme-Linked Immunosorbent Assay MH - Fibrinolytic Agents/*pharmacology MH - Heparin, Low-Molecular-Weight/*pharmacology MH - Lung/metabolism/pathology MH - Male MH - Pulmonary Artery/drug effects/pathology MH - Pulmonary Embolism/*drug therapy/etiology/metabolism MH - Rabbits MH - Urokinase-Type Plasminogen Activator/*pharmacology EDAT- 2014/09/10 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/09/10 06:00 PHST- 2014/09/10 06:00 [entrez] PHST- 2014/09/10 06:00 [pubmed] PHST- 2015/03/31 06:00 [medline] PST - ppublish SO - Zhonghua Jie He He Hu Xi Za Zhi. 2014 Jun;37(6):437-41.